Human papillomavirus vaccine recombinant bivalent - GlaxoSmithKline/MedImmune

Drug Profile

Human papillomavirus vaccine recombinant bivalent - GlaxoSmithKline/MedImmune

Alternative Names: Cervarix; GSK-580299; HPV-16/18 vaccine - GlaxoSmithKline Biologicals; Human papillomavirus (types 6, 18) L1 virus-like particle vaccine - GlaxoSmithKline Biologicals; Human Papillomavirus 16/18 L1 AS04 virus-like particle cervical cancer vaccine - GlaxoSmithKline; Human papillomavirus bivalent (types 16, 18) recombinant vaccine - GlaxoSmithKline Biologicals; MEDI 517; MEDI-517 HPV-16/18 VLP AS04 vaccine

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MedImmune
  • Developer GlaxoSmithKline
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections

Most Recent Events

  • 01 Oct 2016 GlaxoSmithKline completes a phase III trial in Human papillomavirus infections (Prevention, In children) in Mexico, Panama and Colombia (IM) (NCT01627561)
  • 01 Feb 2016 GlaxoSmithKline completes a phase III trial for Human papillomavirus infections and Cervical intraepithelial neoplasia (Prevention) in China (NCT00779766)
  • 01 Jul 2015 GlaxoSmithKline terminates a phase III trial in Cervical intraepithelial neoplasia in Russia prior to enrolment initiation (NCT02082639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top